Kleem Chaudhary has been appointed chief business officer of Cambridge, MA-based Checkmate Pharmaceuticals. He was most recently head of business development & licensing at Biogen (NASDAQ: [[ticker:BIIB]]). Chaudhary’s experience also includes positions at Takeda Pharmaceutical (NYSE: [[ticker:TAK]]) and Novartis (NYSE: [[ticker:NVS]]). Checkmate’s lead drug CMP-001, a type of cancer drug called an oligonucleotide, is in early-stage testing in multiple solid tumors.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
